Lilly Marks is Independent Director of the Company since June 2015. Since 2010, Ms. Marks has served as Vice President for Health Affairs for the University of Colorado and Anschutz Medical Campus, which includes the university’s Schools of Medicine, Dental Medicine, Pharmacy, Public Health, College of Nursing and Graduate School and the University of Colorado Hospital and Children’s Hospital Colorado. Prior to her health campus leadership role, Ms. Marks spent two decades as both Senior Associate Dean for Finance and Administration at the School Of Medicine and Executive Director of University Physicians, Inc., the 501(c)(3) faculty practice plan. Ms. Marks has served as Chair, Board of Directors of the University of Colorado Hospital and is currently chair of the board of the Association of American Medical Colleges and is a board member of the Board of Directors of the Federal Reserve Bank of Kansas City, the Fitzsimons Redevelopment Authority, the Association of Academic Health Centers (AAHC), the Global Down Syndrome Foundation, and the Rose Community Foundation. She is also a member of the AAMC Advisory Panel on Research and is a trustee of the University of Colorado Foundation.
As the Independent Director of Orthofix Medical Inc, the total compensation of Lilly Marks at Orthofix Medical Inc is $250,558. There are 13 executives at Orthofix Medical Inc getting paid more, with Jon Serbousek having the highest compensation of $4,076,200.
Lilly Marks is 72, she's been the Independent Director of Orthofix Medical Inc since 2015. There are 1 older and 16 younger executives at Orthofix Medical Inc. The oldest executive at Orthofix Medical Inc is Ronald Matricaria, 77, who is the Independent Chairman of the Board.
Lilly's mailing address filed with the SEC is 3451 PLANO PARKWAY, , LEWISVILLE, TX, 75056.
Over the last 22 years, insiders at Orthofix Medical Inc have traded over $19,062,472 worth of Orthofix Medical Inc stock and bought 182,076 units worth $5,806,101 . The most active insiders traders include Stuart Essig, Charles R. Kummeth и Alexis V Lukianov. On average, Orthofix Medical Inc executives and independent directors trade stock every 53 days with the average trade being worth of $179,237. The most recent stock trade was executed by Kevin J. Kenny on 8 January 2024, trading 5,959 units of OFIX stock currently worth $103,687.
orthofix international began in a small farmhouse in verona italy in 1980 when orthopedic researcher giovanni de bastiani recognized the bone’s natural repair capability, a concept he called “dynamization” and with that in mind, he created the first external fixation device. today, orthofix has grown to more than 900 employees with locations in the u.s., italy, germany, france, the uk, brazil, australia and puerto rico. our products help patients in 70 countries around the world. the company is comprised of four strategic business units; biostim, biologics, extremity fixation and spine fixation. our products are widely distributed via the company's sales representatives, distributors and subsidiaries. at orthofix we are committed to clinical research and driven by new product introductions. we are proud of our strong partnerships with organizations such as the texas scottish rite hospital for children in dallas and the musculoskeletal transplant foundation. we take pride in developing
Orthofix Medical Inc executives and other stock owners filed with the SEC include: